

SCN 2016 Funding Results: Impact Research Program

Investigators	Project Stream	Project Title	SCN Funds Allocated
Liam Brunham - UBC (Principal Investigator) CI: Glen Tibbits – SFU	Clinical Translation	Using human pluripotent stem cell-derived cardiomyocytes to investigate the mechanisms of ibrutinib-induced atrial fibrillation	\$ 100,000
Timothy Caulfield – U of A (Principal Investigator) CI: Amy Zarzeczny – U of R	Public Policy	Stem Cells and Misleading Marketing Claims	\$ 50,000
Colin Crist – McGill (Principal Investigator) CI: Jean-Philip Lumb – McGill	Clinical Translation	Activation of muscle stem cells by pharmacological inhibitors of eIF2a phosphorylation	\$ 99,842
Lucie Germain – Laval U (Principal Investigator) CI: Bartha Knoppers – McGill	Clinical Translation	Treatment of Patients with Corneal Limbal Stem Cell Deficiencies using Cultured Epithelial Corneal Autografts	\$100,000
Kristin Hope – McMaster (Principal Investigator)	Commercialization	Methods and Compositions for Expansion of Human Hematopoietic Stem and Progenitor Cells	\$ 100,000
Judy Illes – UBC (Principal Investigator)	Public Policy	Decision-Making in Translation: Urgency, Access, and Evaluation in Off-Label Stem Cell Interventions	\$ 50,000
James D. Johnson – UBC (Principal Investigator)	Clinical Translation	Imaged-based screening to enhance insulin production in human embryonic stem cells	\$ 100,000

Timothy J. Kieffer – UBC (Principal Investigator)	Clinical Translation	Biodistribution of Differentiated Stem Cells Following Subcutaneous Transplant	\$ 100,000
Megan Levings – UBC (Principal Investigator) CI: Lori West – U of A	Clinical Translation	Garbage To Gold: Expansion of Therapeutic Regulatory T Cells From Discarded Thymus	\$ 100,000
Joanne Matsubara – UBC (Principal Investigator) CI: Marinko Sarunic – SFU	Commercialization	Treating advanced retinal degeneration - rebuilding multiple co-dependent retinal layers with a single injection of stem-cell-derived-graft	\$ 99,502
Kelly McNaghy – UBC (Principal Investigator)	Clinical Translation	CAR-T cell therapy targeting tumor-specific modifications of Podocalyxin in triple negative breast cancer	\$ 100,000
Ubaka Ogbogu – U of A (Principal Investigator) CI: Amy Zarzeczny – U of R	Public Policy	Regulating the Future: Model Policies for Emerging Stem Cell Research Activities, including Research on Gene-Edited and Reconstituted Embryos	\$ 50,000
Ian Rogers – Mount Sinai Hospital (Principal Investigator)	Commercialization	Improving efficacy and economics of kidney disease therapies using iPS cells	\$ 90,811
Mark Ungrin – U of C (Principal Investigator)	Commercialization	Scalable production of engineered microtissues	\$ 100,000
Sowmya Viswanathan – U of T (Principal Investigator) CI: Paula Foster – UWO	Clinical Translation	Iron labeled-mesenchymal stromal cells for clinical tracking in ameded Phase 1 trial in Osteoarthritis patients	\$ 100,000

CI: Mohit Kapoor – U of T			
Stephanie Willerth – U of V (Principal Investigator)	Commercialization	3D bioprinting of neural tissue from human pluripotent stem cells	\$100,000
Peter Zandstra – U of T (Principal Investigator)	Clinical Translation	Clinical Culture Optimization to Maximize Cord Blood Derived Hematopoietic Stem Cell Expansion	\$ 100,000
CI: Guy Sauvageau – U de M			
CI: Julie Audet – U of T			

*** Project titles posted as per the language of submission**